



This is a press release by Reddy Netherlands B.V. (the “Offeror”), a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd. (“Dr. Reddy's”), and Dr. Reddy's pursuant to Section 13 paragraph 1 of the Dutch Public Takeover Decree (*Besluit openbare biedingen Wft*, the “Decree”) in connection with the recommended public offer (the “Offer”) by the Offeror for all the issued and outstanding ordinary shares (the “Shares”) in the capital of OctoPlus N.V. (“OctoPlus” or the “Company”). This press release does not constitute, or form part of, an offer or any solicitation of an offer, to acquire or subscribe or sell any securities in OctoPlus. The Offer is only made by means of the offer memorandum published on 13 December 2012 (the “Offer Memorandum”). This announcement is not for release, publication, dissemination, or distribution, in whole or in part, in or into Canada and Japan. Capitalised terms not defined in this press release shall have the meaning given thereto in the Offer Memorandum.

## **Dr. Reddy's acquires 82,425 shares in OctoPlus**

**Hyderabad/Amsterdam, 12 February 2013 – With reference to the joint press releases of the Offeror and OctoPlus (NYSE Euronext Amsterdam: OCTO) of 13 December 2012 and 12 February 2013 relating to the Offer, the Offeror announces that it has acquired 82,425 Shares in the course of today at a volume weighed average price of EUR 0.52 per Share, a minimum price of EUR 0.52 per Share and a maximum price of EUR 0.52 per Share.**

Together with the Shares tendered under the Offer and the Shares acquired by the Offeror, this results in the following positions:

	<b>Number of Shares</b>	<b>Percentage of Shares</b>
Shares tendered under the Offer or acquired by the Offeror prior to today's acquisitions	48,808,638	92.7%
Shares acquired on 12 February 2013	82,425	0.2%
<b>Total on 12 February 2013</b>	<b>48,891,063</b>	<b>92.8%</b>

### **Offer Memorandum, Position Statement and further information**

Shareholders are advised to review the Offer Memorandum and the Position Statement and to seek independent advice where appropriate in order to reach a reasoned judgement in respect of the content of the Offer Memorandum, the Position Statement and the Offer itself.

Digital copies of the Offer Memorandum are available on the website of OctoPlus ([www.octoplus.nl](http://www.octoplus.nl)) and Dr. Reddy's ([www.drreddys.com](http://www.drreddys.com)). Copies of the Offer Memorandum are also available free of charge at the offices of OctoPlus and the Exchange Agent at the addresses mentioned below. The Dr. Reddy's and

OctoPlus websites do not constitute a part of, and are not incorporated by reference into, the Offer Memorandum.

Digital copies of the Position Statement and the other documents with respect to the EGM, including the agenda, explanatory notes thereto and the voting results, are available on the website of OctoPlus ([www.octoplus.nl](http://www.octoplus.nl)). Copies of the Position Statement are also available free of charge at the offices of OctoPlus at the address mentioned below.

*OctoPlus N.V.*  
Zernikedreef 12  
2333 CL Leiden  
The Netherlands

*Exchange Agent*  
Kempen & Co N.V.  
Attn. Kempen Agency Services L3  
Beethovenstraat 300  
1077 WZ Amsterdam  
The Netherlands

Telefax: +31 (0)20 348 9549  
E-mail: [kas@kempen.nl](mailto:kas@kempen.nl)

### **Company profile Dr. Reddy's**

Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Over the last fiscal year the company generated revenues of over \$2.0 billion. Through its three businesses – Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information: [www.drreddys.com](http://www.drreddys.com).

### **Company profile OctoPlus**

OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies.

OctoPlus also focuses on the development of long-acting, controlled release versions of known protein therapeutics, peptides and small molecules, including specialty generics. OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. More information about OctoPlus can be found on: [www.octoplus.nl](http://www.octoplus.nl).

### **Further information**

#### **Dr. Reddy's**

For further information about Dr. Reddy's, please contact:

For Investors and Financial Analysts:

Kedar Upadhye: telephone number +91-40-66834297 or send an e-mail to [kedaru@drreddys.com](mailto:kedaru@drreddys.com)

Saunak Savla: telephone number +91-40-49002135 or send an e-mail to [saunaks@drreddys.com](mailto:saunaks@drreddys.com)

Milan Kalawadia (USA): telephone number +1 908-203-4931 or send an e-mail to [mkalawadia@drreddys.com](mailto:mkalawadia@drreddys.com)

For Media:

S Rajan: telephone number +91-40-49002445 or send an e-mail to [rajans@drreddys.com](mailto:rajans@drreddys.com)

#### **OctoPlus**

For further information about OctoPlus, please contact Investor Relations: telephone number +31 (71) 524 1061 or send an e-mail to Investor Relations at [IR@octoplus.nl](mailto:IR@octoplus.nl).

### **Restrictions**

This announcement is for information purposes only and does not constitute an offer or an invitation to acquire or dispose of any securities or investment advice or an inducement to enter into investment activity. This announcement does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire the securities of Dr. Reddy's or OctoPlus in any jurisdiction. The distribution of this press release may, in some countries, be restricted by law or regulation. Accordingly, persons who come into possession of this document should inform themselves of and observe these restrictions. To the fullest extent permitted by applicable law, Dr. Reddy's and OctoPlus disclaim any responsibility or liability for the violation of any such restrictions by any person. Any failure to comply with these restrictions may constitute a violation of the securities laws of that jurisdiction. Neither Dr. Reddy's, nor OctoPlus, nor any of their advisors assumes any responsibility for any violation by any person of any of these restrictions. Any OctoPlus shareholder who is in any doubt as to his position should consult an appropriate professional advisor without delay. This announcement is not to be published or distributed in or to Canada and Japan.

### **Notice to US holders of Shares**

The Offer will be made for the securities of a Dutch company and is subject to Dutch disclosure requirements, which are different from those of the United States. Some of the financial information included in this announcement has been prepared in accordance with International Financial Reporting Standards and thus may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with generally accepted accounting principles in the

United States. The Offer will be made in the United States pursuant to the applicable US tender offer rules and otherwise in accordance with the requirements of the Dutch Public Takeover Decree. Accordingly, the Offer will be subject to disclosure and other procedural requirements, including with respect to withdrawal rights, offer timetable, settlement procedures and timing of payments, that are different from those applicable under US domestic tender offer procedures and law.

The receipt of cash pursuant to the Offer by a US holder of Shares may be a taxable transaction for US federal income tax purposes and under applicable state and local, as well as foreign and other tax laws. Each holder of Shares is urged to consult his independent professional advisor immediately regarding the tax consequences of acceptance of the offer.

It may be difficult for US holders of Shares to enforce their rights and claims arising out of the US federal securities laws, since OctoPlus is located in a country other than the United States, and some or all of its officers and directors may be residents of a country other than the United States. US holders of Shares may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws. Further, it may be difficult to compel a non-US company and its affiliates to subject themselves to a US court's judgment.

In accordance with normal Dutch practice and pursuant to Rule 14e-5(b) of the Securities Exchange Act of 1934, Dr. Reddy's or its nominees, or its brokers (acting as agents), may from time to time make certain purchases of, or arrangements to purchase, Shares outside of the United States, other than pursuant to the Offer, during the period in which the Offer remains open for acceptance or thereafter. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices. Any information about such purchases will be disclosed as required in the Netherlands, will be reported to the Netherlands Authority for the Financial Markets (*Stichting Autoriteit Financiële Markten*) and disclosed by press release, to the extent required.

### **Forward Looking Statements**

This press release may include "forward-looking statements" and language indicating trends, such as "anticipated" and "expected." Although Dr. Reddy's and OctoPlus believe that the assumptions upon which the irrelative financial information and their respective forward-looking statements are based are reasonable, they can give no assurance that these assumptions will prove to be correct. Neither Dr. Reddy's nor OctoPlus, nor any of their advisors accepts any responsibility for any financial information contained in this press release relating to the business or operations or results or financial condition of the other or their respective groups.